Observational trial to assess the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
04 Jun 2019 Preliminary results (n=200) published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
05 Jun 2018 Interim results (n=176) presented at the 54th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com